KROS Valuation

Keros Therapeutics Inc

Add to Watchlist

Advanced Chart

15.900

+0.34(2.185%)1D

Overview
Forecast
Valuation
Earnings

KROS Relative Valuation

KROS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KROS is overvalued; if below, it's undervalued.

Historical Valuation

Keros Therapeutics Inc (KROS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.80. The fair price of Keros Therapeutics Inc (KROS) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：15.90

Fair

-3.36

Trailing

Forward

0.65

EV/EBITDA

Keros Therapeutics Inc. (KROS) has a current EV/EBITDA of 0.65. The 5-year average EV/EBITDA is -2.52. The thresholds are as follows: Strongly Undervalued below -10.16, Undervalued between -10.16 and -6.34, Fairly Valued between 1.30 and -6.34, Overvalued between 1.30 and 5.12, and Strongly Overvalued above 5.12. The current Forward EV/EBITDA of 0.65 falls within the Historic Trend Line -Fairly Valued range.

0.19

EV/EBIT

Keros Therapeutics Inc. (KROS) has a current EV/EBIT of 0.19. The 5-year average EV/EBIT is -7.87. The thresholds are as follows: Strongly Undervalued below -19.79, Undervalued between -19.79 and -13.83, Fairly Valued between -1.90 and -13.83, Overvalued between -1.90 and 4.06, and Strongly Overvalued above 4.06. The current Forward EV/EBIT of 0.19 falls within the Overvalued range.

85.40

Keros Therapeutics Inc. (KROS) has a current PS of 85.40. The 5-year average PS is 17315.62. The thresholds are as follows: Strongly Undervalued below -122538.59, Undervalued between -122538.59 and -52611.49, Fairly Valued between 87242.73 and -52611.49, Overvalued between 87242.73 and 157169.84, and Strongly Overvalued above 157169.84. The current Forward PS of 85.40 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Keros Therapeutics Inc. (KROS) has a current P/OCF of 0.00. The 5-year average P/OCF is -7.57. The thresholds are as follows: Strongly Undervalued below -23.32, Undervalued between -23.32 and -15.45, Fairly Valued between 0.30 and -15.45, Overvalued between 0.30 and 8.18, and Strongly Overvalued above 8.18. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-10.67

P/FCF

Keros Therapeutics Inc. (KROS) has a current P/FCF of -10.67. The 5-year average P/FCF is -11.79. The thresholds are as follows: Strongly Undervalued below -23.89, Undervalued between -23.89 and -17.84, Fairly Valued between -5.74 and -17.84, Overvalued between -5.74 and 0.32, and Strongly Overvalued above 0.32. The current Forward P/FCF of -10.67 falls within the Historic Trend Line -Fairly Valued range.

Keros Therapeutics Inc (KROS) has a current Price-to-Book (P/B) ratio of 0.91. Compared to its 3-year average P/B ratio of 3.47 , the current P/B ratio is approximately -73.65% higher. Relative to its 5-year average P/B ratio of 4.25, the current P/B ratio is about -78.49% higher. Keros Therapeutics Inc (KROS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.95% , the current FCF yield is about -100.00% lower.

0.91

P/B

Median3y

3.47

Median5y

4.25

8.40

FCF Yield

Median3y

-8.58

Median5y

-6.95

Competitors Valuation Multiple

The average P/S ratio for KROS's competitors is 0.00, providing a benchmark for relative valuation. Keros Therapeutics Inc Corp (KROS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 49002.70%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KROS.O

Keros Therapeutics Inc

SIGA Technologies Inc

Rigel Pharmaceuticals Inc

Gyre Therapeutics Inc

Kalvista Pharmaceuticals Inc

Loss

661.85M

Performance Decomposition

Market capitalization of KROS decreased by 72.62% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 37.00K to 18.17M.

The secondary factor is the Margin Expansion, contributed -99.86%to the performance.

Overall, the performance of KROS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

49002.70%

37.00K → 18.17M

Revenue Growth

-99.86%

-122.32K → -168.96

Margin Expansion

-48975.46%

-0.07 → 34.17

P/E Change

-72.62%